Machina Capital S.A.S. Grows Stock Holdings in Kenvue Inc. $KVUE

Machina Capital S.A.S. lifted its position in shares of Kenvue Inc. (NYSE:KVUE) by 697.0% in the 2nd quarter, Holdings Channel.com reports. The firm owned 121,431 shares of the company’s stock after purchasing an additional 106,195 shares during the period. Machina Capital S.A.S.’s holdings in Kenvue were worth $2,542,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of KVUE. Vanguard Group Inc. lifted its position in Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock valued at $5,494,882,000 after acquiring an additional 10,600,682 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Kenvue by 2.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company’s stock valued at $613,882,000 after acquiring an additional 633,461 shares during the last quarter. Boston Partners lifted its position in Kenvue by 7.4% in the first quarter. Boston Partners now owns 25,346,453 shares of the company’s stock valued at $606,920,000 after acquiring an additional 1,750,490 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Kenvue by 11.6% in the first quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company’s stock valued at $597,395,000 after acquiring an additional 2,597,920 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in Kenvue by 15.7% in the first quarter. American Century Companies Inc. now owns 21,828,854 shares of the company’s stock valued at $523,456,000 after acquiring an additional 2,961,716 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on KVUE shares. Royal Bank Of Canada reduced their price target on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research report on Friday, August 8th. JPMorgan Chase & Co. dropped their price objective on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Jefferies Financial Group dropped their price objective on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Monday, October 27th. Citigroup dropped their price objective on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, October 9th. Finally, Canaccord Genuity Group restated a “hold” rating and issued a $15.00 price objective (down from $26.00) on shares of Kenvue in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $20.17.

Kenvue Trading Up 1.1%

Shares of Kenvue stock opened at $14.40 on Monday. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The company’s 50-day simple moving average is $17.21 and its 200-day simple moving average is $20.50. The firm has a market cap of $27.63 billion, a price-to-earnings ratio of 19.45, a price-to-earnings-growth ratio of 2.07 and a beta of 0.72.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The business had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business’s revenue was down 4.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 26th. Investors of record on Wednesday, November 12th will be issued a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a yield of 5.8%. Kenvue’s payout ratio is currently 112.16%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.